Go to hub
Simply Wall St
3 min read
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.
Danaher (NYSE:DHR) has entered an investment partnership with Automata, an AI ready lab automation company.
The collaboration focuses on combining Automata’s automation systems with Danaher’s instruments, reagents, and software.
The goal is to offer end to end, AI driven lab solutions that support faster scientific workflows and research.
For you as an investor, this move sits at the intersection of life sciences and automation, two areas getting a lot of attention as labs look to scale complex workflows. Danaher already operates across instruments, consumables, and software, and tying that portfolio to AI focused automation reflects how labs are working to manage more data heavy, high throughput activity.
Looking ahead, the partnership provides Danaher with another avenue to reach customers who prefer integrated, automated lab setups rather than standalone tools. The pace of any resulting product adoption and revenue contribution will depend on execution, customer budgets, and how effectively these combined systems fit into existing lab infrastructure.
Stay updated on the most important news stories for Danaher by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Danaher.
NYSE:DHR Earnings & Revenue Growth as at Jan 2026
How Danaher stacks up against its biggest competitors
For Danaher, taking a stake in Automata appears aligned with its push into higher value workflows in bioprocessing, diagnostics and life sciences, especially after a year where full year 2025 net income of US$3,614 million was below the prior year’s US$3,899 million despite sales of US$24,568 million versus US$23,875 million. Tying Automata’s AI ready lab automation to Danaher’s instruments and consumables gives the company another way to deepen relationships with pharma and research customers that might otherwise lean toward integrated setups from peers like Thermo Fisher Scientific or Agilent Technologies.
The partnership lines up with the existing story of Danaher as a life sciences and diagnostics platform that leans heavily on consumables, services and recurring workflows rather than one off hardware. It also sits alongside recent efforts to focus the portfolio after the Veralto divestiture, reinforcing the idea that management is concentrating capital on tools that can support long term demand in precision medicine and AI supported diagnostics.
Potential for deeper integration of instruments, software and automation that can support recurring consumables usage over time.
The tie up gives Danaher another route to participate in AI focused lab spending, which management has already linked to product development and new workflows.
Execution risk if Automata’s platforms are slow to gain traction, especially after 2025 earnings per share softened compared to the prior year.
Competitive response from established players like Thermo Fisher Scientific and Agilent Technologies that also offer automated and software heavy lab solutions.
From here, you may want to watch for concrete product launches that explicitly combine Automata systems with Danaher brands, any commentary in upcoming quarters on early customer wins and whether management links this partnership to its 2026 core revenue growth guidance of 3% to 6%. If you want to see how other investors frame Danaher’s long term story and how this update fits into it, you can check community narratives on Danaher’s dedicated page.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include DHR.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Terms and Privacy Policy